* Vaxart Inc is expected to show a fall in quarterly revenue when it reports results on October 31 (estimated) for the period ending September 30 2024
* The South San Francisco California-based company is expected to report a 59.5% decrease in revenue to $850 thousand from $2.1 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Vaxart Inc is for a loss of 10 cents per share.
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Vaxart Inc is $4.00, above its last closing price of $0.84.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 0.01 -0.03 -0.09 Missed -237.5
Jan. 1 2024 -0.14 -0.14 -0.14 Met 0
Dec. 31 2023 -0.16 -0.14 -0.12 Beat 17.2
Sep. 30 2023 -0.18 -0.18 -0.11 Beat 37.7
Jun. -0.18 -0.18 -0.16 Beat 11.1
30 2023
Mar. 31 2023 -0.18 -0.19 -0.19 Met -1.8
Jan. 1 0001 -0.22 -0.23 -0.18 Beat 20.9
Sep. 30 2022 -0.25 -0.24 -0.23 Beat 5.2
This summary was machine generated October 29 at 11:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。